Optimizing Immune Checkpoint Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer
PCE
English - June 30, 2022 12:00 - 12 minutes - 11.9 MB - ★★★★ - 6 ratingsCourses Education Science Life Sciences app education np education podcasts for credit app medicine pa education np medicine pa medicine ce podcasts app podcasts cme podcasts Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: An Update from ASCO 2022
Next Episode: ASCO 2022: Advances in CLL/SLL
In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events.
Topics include:
Currently approved ICIsRole of biomarker and PD-L1 testing in advanced NSCLCStrategies to individualize ICI treatment for patients with advanced NSCLCStrategies for identifying and managing immune-related adverse events in patients treated with ICIPresenter:
Sandip P. Patel, MD
Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California – San Diego
La Jolla, California
Link to full program:
https://bit.ly/39vuCHC